Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Michigan

Sites in Ann Arbor, MI

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1232
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Michigan, Ann Arbor, MI
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Michigan, Ann Arbor, MI. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 721–732 of 1,232 matching trials with a site at University of Michigan, Ann Arbor, MI.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

NCT06413706
Site status not listed — check the official record
View directory record Official record
Conditions
Glioma
Interventions
Abemaciclib, Temozolomide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
0 Years to 20 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Orange, California • Palo Alto, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Recruiting Phase 2 Interventional

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

NCT05269628
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Sclerosis, Sleep, Pain
Interventions
Cannabidiol (CBD), Tetrahydrocannabinol (THC), Placebo CBD, Placebo THC
Drug
Lead sponsor
Tiffany J. Braley, MD, MS
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Recruiting Phase 2 Interventional

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT05467891
Status at this site: Recruiting
View directory record Official record
Conditions
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Ribociclib, Fulvestrant, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Oana Danciu
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Recruiting Phase 3 Interventional

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

NCT03583710
Status at this site: Recruiting
View directory record Official record
Conditions
ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma
Interventions
Cisplatin, Etoposide, Mitotane, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Active, not recruiting No phase listed Interventional

Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

NCT00499330
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Cancer
Interventions
lobectomy, segmentectomy or wedge resection
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
373
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 245 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Recruiting No phase listed Observational

MEASuRE: Metreleptin Effectiveness And Safety Registry

NCT02325674
Status at this site: Recruiting
View directory record Official record
Conditions
Generalised Lipodystrophy, Partial Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Recruiting Phase 2 Interventional

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer

NCT06356155
Status at this site: Recruiting
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Enfortumab vedotin, Pembrolizumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Recruiting Not applicable Interventional

Improving Coping to Reduce Suicide Risk Following ED Discharge

NCT06614946
Status at this site: Recruiting
View directory record Official record
Conditions
Suicidal, Suicide, Attempted, Suicidal Ideation
Interventions
Electronic Safety Plan (ESP), Text support
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Recruiting Not applicable Interventional

Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors

NCT06941324
Status at this site: Recruiting
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Behavioral Intervention, Best Practice, Communication Intervention, Discussion, Health Promotion and Education, Interview, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
15 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Recruiting Not applicable Interventional

Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

NCT06784466
Status at this site: Recruiting
View directory record Official record
Conditions
Atrial Fibrillation (AF), Persistant Atrial Fibrillation, Paroxysmal AF
Interventions
Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
Device
Lead sponsor
Arga Medtech SA
Industry
Eligibility
18 Years to 80 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Recruiting Phase 3 Interventional

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

NCT05451004
Status at this site: Recruiting
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Lymphatic Mapping with SPECT-CT, Ipsilateral and Contralateral Neck
Other · Radiation
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
28
States / cities
Corona, California • Duarte, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 4, 2026, 5:24 AM EST
Active, not recruiting No phase listed Observational

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

NCT05388708
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Interventions
ECMO support, PROSpect protocolized therapies
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
14 Days to 20 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 4, 2026, 5:24 AM EST

About this University of Michigan institution page

What this page lists
ClinicalTrials.gov records that list University of Michigan in Ann Arbor, MI as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.